Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.Financial_Report.xls
10-Q - FORM 10-Q - ProUroCare Medical Inc.v325918_10q.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R28.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R32.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R30.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R31.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R29.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R27.htm
XML - IDEA: XBRL DOCUMENT - ProUroCare Medical Inc.R26.htm
EX-31.2 - EXHIBIT 31.2 - ProUroCare Medical Inc.v325918_ex31-2.htm
EX-32.1 - EXHIBIT 32.1 - ProUroCare Medical Inc.v325918_ex32-1.htm
EX-31.1 - EXHIBIT 31.1 - ProUroCare Medical Inc.v325918_ex31-1.htm
EX-10.4 - EXHIBIT 10.4 - ProUroCare Medical Inc.v325918_ex10-4.htm
v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
9 Months Ended 157 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Cash flows from operating activities:      
Net loss $ (2,323,625) $ (1,534,559) $ (38,286,094)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 306 414 22,363
Gain on sale of furniture and equipment 0 0 (2,200)
Stock-based compensation 6,981 129,559 2,743,630
Common stock issued for services rendered 98,053 43,749 486,764
Common stock issued for debt issuance cost 0 2,697 166,831
Notes payable issued for intangibles expensed as research and development 0 0 150,000
Notes payable issued for interest 1,000 0 1,000
Convertible note issued for services rendered 0 0 2,700
Warrants issued for services 0 61,050 683,370
Warrants issued for debt issuance cost 0 0 1,782,828
Warrants issued for early warrant exercise incentive 0 0 2,727,103
Units issued for interest 0 0 8,700
Units issued for debt extinguisment 0 0 870,981
Amortization of original issue discount on debt 11,609 0 2,648,941
Amortization of debt issuance costs 562,276 322,081 3,664,899
Bargain conversion option added to note payable - related parties for debt extinguishment 0 0 48,214
Write-off debt issuance cost for debt extinguishment 0 0 42,797
Write-off of deferred offering cost 0 0 59,696
License rights expensed as research and development, paid by issuance of common stock to CS Medical Technologies, LLC 0 0 475,000
License rights expensed as research and development, paid by issuance of common stock to Profile, LLC 0 0 1,713,600
Changes in operating assets and liabilities:      
Other current assets (24,660) (2,280) (91,922)
Accounts payable 81,506 130,094 905,533
Accrued development expense 577,500 0 2,642,885
Accrued expenses 185,946 154,693 1,243,187
Net cash used in operating activities (823,108) (692,502) (15,289,194)
Cash flows from investing activities:      
Purchases of equipment and furniture 0 0 (36,767)
Deposit into a restricted cash account 0 0 (44,214)
Withdrawal from a restricted cash account 0 0 44,214
Net cash used in investing activities 0 0 (36,767)
Cash flows from financing activities:      
Proceeds of note payable, bank 0 100,000 700,000
Payments of note payable, bank (200,000) 0 (1,700,000)
Proceeds of notes payable 295,627 99,000 1,370,100
Payment of notes payable (74,172) (130,920) (1,755,906)
Proceeds of notes payable - related parties 0 0 1,096,596
Payments of notes payable - related parties 0 0 (282,800)
Proceeds from long-term convertible notes payable and bank debt 0 75,000 4,357,362
Proceeds from long-term convertible notes payable - related parties 200,000 150,000 1,913,500
Payments on long-term bank debt 0 0 (600,000)
Net proceeds from warrants 0 0 104,500
Proceeds from exercise of warrants 0 0 2,223,788
Payments for debt issuance costs 0 (18,000) (793,227)
Payment for rescission of common stock 0 0 (100,000)
Payments for offering expenses 0 0 (651,962)
Cost of reverse merger 0 0 (162,556)
Net proceeds from issuance of common stock 707,000 0 9,737,756
Net cash provided by financing activities 928,455 275,080 15,457,151
Net increase (decrease) in cash 105,347 (417,422) 131,190
Cash, beginning of the period 25,843 419,136 0
Cash, end of the period $ 131,190 $ 1,714 $ 131,190